Investment Thesis
Early-stage pharmaceutical company with unsustainable burn rate ($3.4M operating cash outflow quarterly) against minimal revenue ($1.5M) and massive losses ($77.2M). Despite a clean balance sheet with $84.4M in equity and no debt, the company has only ~2 years of cash runway at current burn rate with zero revenue growth, indicating unproven commercialization capability and high risk of dilutive financing or insolvency.
Strengths
- No debt with clean capital structure (0% debt/equity ratio)
- Strong short-term liquidity with 27.28x current ratio to fund near-term operations
- Substantial asset base ($87.4M) provides runway for continued R&D investment
Risks
- Unsustainable burn rate of $3.4M quarterly against minimal $1.5M revenue indicates ~2 year cash runway
- Zero revenue growth YoY with no evidence of commercial traction or market validation
- Extreme losses ($77.2M net loss, -5144% net margin) suggest major R&D write-downs or failed development programs
- Negative operating cash flow signals company cannot fund operations from core business
- Early-stage pharmaceutical company lacks proven ability to commercialize products in competitive market
Key Metrics to Watch
- Quarterly revenue trend and path to positive revenue growth
- Monthly burn rate and cash runway remaining before need for external financing
- Operating cash flow and working capital management improvements
- R&D pipeline milestones and any clinical trial updates indicating product progress
Financial Metrics
Revenue
1.5M
Net Income
-77.2M
EPS (Diluted)
$-0.46
Free Cash Flow
-3.5M
Total Assets
87.4M
Cash
6.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-321.1%
Net Margin
-5,144.4%
ROE
-91.5%
ROA
-88.3%
FCF Margin
-235.3%
Balance Sheet & Liquidity
Current Ratio
27.28x
Quick Ratio
27.28x
Debt/Equity
0.00x
Debt/Assets
3.4%
Interest Coverage
-89.20x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:02:42.867583 |
Data as of: 2026-03-31 |
Powered by Claude AI